PCSK9 and familial hypercholesterolemia: The basis for this recommendation is the reduced efficacy of PCSK9 inhibition in lowering LDL-cholesterol lowering in these HoFH who were enrolled in the Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia trial.